Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Symeonidis

Showing results (521-530 of 578) with videos related to

Pageof 58
Sort By:
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Journal of Clinical Medicine|April 30, 2021
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" StudyEvangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|July 26, 2016
Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON studyG Andrikopoulos, D Terentes-Printzios, S Tzeis, et al.
Pageof 58

Showing results (521-530 of 578) with videos related to

Sort By:
Pageof 58
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Journal of Clinical Medicine|April 30, 2021
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" StudyEvangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Blood Cancer Journal|March 11, 2018
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupEirini Katodritou, Evangelos Terpos, Sossana Delimpasi, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|July 26, 2016
Epidemiological characteristics, management and early outcomes of acute coronary syndromes in Greece: The PHAETHON studyG Andrikopoulos, D Terentes-Printzios, S Tzeis, et al.
Pageof 58